Asana BioSciences, an independent member of the Amneal Alliance of Companies, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. Asana is a research and development company specializing in the discovery and development of new chemical and biological entities. The company’s portfolio consists of multiple compounds for oncology and pain indications that are ready to enter clinical trials. Asana is based in Bridgewater, NJ and led by Dr. Sandeep Gupta, Chief Executive Officer, who, until recently, was the Senior Vice President of Discovery and Early Development at Endo Pharmaceuticals.

Dr. Gupta explained, “Asana’s mission is to develop novel and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients. Our team consists of highly experienced scientists who have successfully executed several drug discovery and clinical development projects. I am very excited about this portfolio and am looking forward to initiating our First-in-Man trials for our lead asset and moving other assets into clinical development.”

“I’m pleased to announce the launch of Asana BioSciences, which expands the Amneal Alliance of Companies’ footprint in pharmaceutical drug discovery, in addition to its generic, specialty and biologics capabilities,” said Chintu Patel, Co-CEO and Co-Chairman of Amneal Pharmaceuticals LLC, a member of the Amneal Alliance of Companies.